Hookipa Historical Financial Ratios
| HOOK Stock | USD 2.58 0.06 2.38% |
Hookipa Pharma is recently reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.81 or Days Sales Outstanding of 300 will help investors to properly organize and evaluate Hookipa Pharma financial condition quickly.
Hookipa |
About Hookipa Financial Ratios Analysis
Hookipa PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Hookipa Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Hookipa financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Hookipa Pharma history.
Hookipa Pharma Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Hookipa Pharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Hookipa Pharma sales, a figure that is much harder to manipulate than other Hookipa Pharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Payout Ratio
Payout Ratio is the proportion of Hookipa Pharma earnings paid out as dividends to shareholders. Payout Ratio is typically expressed as a percentage but can be shown as dividends paid out as a proportion of cash flow. The payout ratio is used to determine the sustainability of Hookipa Pharma dividend payments. A lower payout ratio is generally preferable to a higher payout ratio, with a ratio greater than 100% indicating Hookipa Pharma is paying out more in dividends than it makes in net income.Most ratios from Hookipa Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Hookipa Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.At this time, Hookipa Pharma's Days Payables Outstanding is quite stable compared to the past year. Income Quality is expected to rise to 0.88 this year, although the value of Days Sales Outstanding will most likely fall to 299.96.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 3.69 | 4.13 | 3.5 | 3.33 | Net Debt To EBITDA | 0.8 | 1.77 | 1.43 | 2.71 |
Hookipa Pharma fundamentals Correlations
Click cells to compare fundamentals
Hookipa Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hookipa Pharma fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 182.91 | 14.77 | 4.16 | 3.73 | 3.8 | 3.61 | |
| Ptb Ratio | 18.53 | 1.85 | 0.86 | 0.52 | 0.85 | 0.81 | |
| Days Sales Outstanding | 297.3 | 385.0 | 418.78 | 563.86 | 349.44 | 299.96 | |
| Book Value Per Share | 6.6 | 59.85 | 27.23 | 15.63 | 9.51 | 13.59 | |
| Free Cash Flow Yield | (0.02) | (0.14) | (1.03) | (0.47) | (0.81) | (0.77) | |
| Operating Cash Flow Per Share | (2.34) | (15.08) | (20.07) | (3.05) | (6.09) | (6.39) | |
| Capex To Depreciation | 3.36 | 1.39 | 0.57 | 2.71 | 1.17 | 2.18 | |
| Pb Ratio | 18.53 | 1.85 | 0.86 | 0.52 | 0.85 | 0.81 | |
| Ev To Sales | 174.32 | 8.0 | 1.1 | (3.78) | (1.69) | (1.6) | |
| Free Cash Flow Per Share | (2.45) | (15.99) | (23.89) | (3.81) | (6.53) | (6.85) | |
| Roic | (0.33) | (0.25) | (0.86) | (0.69) | (1.06) | (1.01) | |
| Net Income Per Share | (2.41) | (16.9) | (23.0) | (9.9) | (8.63) | (9.06) | |
| Payables Turnover | 6.01 | 49.06 | 6.63 | 0.53 | 0.66 | 0.28 | |
| Sales General And Administrative To Revenue | 1.4 | 0.92 | 0.94 | 1.32 | 0.93 | 1.18 | |
| Research And Ddevelopement To Revenue | 3.88 | 2.8 | 4.49 | 4.82 | 4.29 | 3.09 | |
| Capex To Revenue | 0.17 | 0.12 | 0.68 | 0.35 | 0.21 | 0.24 | |
| Cash Per Share | 6.34 | 54.89 | 20.34 | 17.3 | 12.39 | 13.49 | |
| Pocfratio | (52.34) | (7.35) | (1.16) | (2.66) | (1.33) | (1.4) | |
| Interest Coverage | (58.25) | (67.79) | (90.95) | (106.48) | (308.18) | (292.77) | |
| Capex To Operating Cash Flow | (0.0479) | (0.0603) | (0.19) | (0.25) | (0.0723) | (0.0759) | |
| Pfcf Ratio | (49.95) | (6.94) | (0.98) | (2.12) | (1.24) | (1.3) | |
| Days Payables Outstanding | 7.44 | 55.02 | 689.25 | 556.11 | 1.3K | 1.3K | |
| Income Quality | 0.97 | 0.89 | 0.87 | 0.31 | 0.71 | 0.88 | |
| Ev To Operating Cash Flow | (49.88) | (3.98) | (0.31) | 2.69 | 0.59 | 0.62 | |
| Pe Ratio | (50.75) | (6.56) | (1.01) | (0.82) | (0.94) | (0.99) | |
| Return On Tangible Assets | (0.3) | (0.23) | (0.6) | (0.38) | (0.51) | (0.53) | |
| Ev To Free Cash Flow | (47.6) | (3.75) | (0.26) | 2.15 | 0.55 | 0.58 | |
| Earnings Yield | (0.0197) | (0.15) | (0.99) | (1.22) | (1.07) | (1.12) | |
| Net Debt To E B I T D A | 2.62 | 3.39 | 0.8 | 1.77 | 1.43 | 2.71 | |
| Current Ratio | 8.68 | 8.11 | 3.69 | 4.13 | 3.5 | 3.33 | |
| Tangible Book Value Per Share | 6.6 | 59.85 | 27.23 | 15.63 | 9.51 | 13.59 | |
| Receivables Turnover | 1.23 | 0.95 | 0.87 | 0.65 | 1.04 | 1.16 | |
| Graham Number | 18.92 | 150.86 | 118.72 | 59.01 | 42.96 | 46.29 | |
| Shareholders Equity Per Share | 6.6 | 59.85 | 27.23 | 15.63 | 9.51 | 13.59 | |
| Debt To Equity | 0.04 | 0.0291 | 0.0559 | 0.0409 | 0.0307 | 0.0238 | |
| Capex Per Share | 0.11 | 0.91 | 3.82 | 0.77 | 0.44 | 0.71 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.67) | Revenue Per Share 4.403 | Quarterly Revenue Growth (0.52) | Return On Assets (0.20) | Return On Equity (0.49) |
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.